<DOC>
	<DOCNO>NCT00239720</DOCNO>
	<brief_summary>hOKT3gamma1 ( Ala-Ala ) man-made antibody commonly use prevent organ rejection . The purpose study determine whether hOKT3gamma1 ( Ala-Ala ) safe effective psoriatic arthritis patient unable control arthritis methotrexate azathioprine .</brief_summary>
	<brief_title>hOKT3gamma1 ( Ala-Ala ) Treatment Psoriatic Arthritis</brief_title>
	<detailed_description>Psoriatic arthritis form inflammatory arthritis affect approximately 7 % people psoriasis . Treatment typically include drug methotrexate , azathioprine , etanercept , suppress immune system nonspecific fashion attempt control immune response cause disease . In severe case psoriatic arthritis , drug adequately control disease , often require patient undergo continuous treatment prevent combat disease activity . hOKT3gamma1 ( Ala-Ala ) genetically engineer monoclonal antibody direct CD3 antigen T cell . hOKT3gamma1 ( Ala-Ala ) specifically target immune cell actively involved destructive immune response , cause psoriatic arthritis . In small pilot study eight people psoriatic arthritis receive 2-week course hOKT3gamma1 ( Ala-Ala ) , drug appear safe cause serious side effect . This study test safety efficacy hOKT3gamma1 ( Ala-Ala ) alleviate symptom psoriatic arthritis patient . This study last 2 year . Individuals psoriatic arthritis receive methotrexate azathioprine therapy active disease eligible participate . Participants randomly assign receive hOKT3gamma1 ( Ala-Ala ) placebo . Participants receive 5-day treatment drug placebo every month first 4 month study . There 5 study visit 2 year assess safety effectiveness hOKT3gamma1 ( Ala-Ala ) evaluate laboratory measure relate underlie immune problem cause psoriatic arthritis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Diagnosis psoriatic arthritis . Participants need concurrent psoriasis participate study . Active inflammation 3 joint Currently receive ongoing therapy methotrexate azathioprine Willing use acceptable form contraception Active infection HIV , hepatitis C virus , hepatitis B virus Uncompensated heart failure recent myocardial infarction ( heart attack ) within 6 month prior study entry Certain serious illness cancer Participation another clinical trial within 6 week prior study entry Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Psoriatic</keyword>
	<keyword>PsA</keyword>
</DOC>